United States

Profile: Osiris Therapeutics Inc (OSIR.OQ)

OSIR.OQ on NASDAQ Stock Exchange Global Market

24 Feb 2017
Change (% chg)

$0.03 (+0.53%)
Prev Close
Day's High
Day's Low
Avg. Vol
52-wk High
52-wk Low

Osiris Therapeutics, Inc., incorporated on March 30, 2010, is a cellular and regenerative medicine company. The Company is focused on researching, developing and marketing products in the wound, orthopedic, and sports medicine markets. The Company operates through Biosurgery business segment, which focuses on products for wound care, orthopedics, and sports medicine to harness the ability of cells and novel constructs to promote the body's natural healing. The Company's products include Grafix, Stravix, TruSkin, Cartiform and BIO4. The Company produces and distributes Grafix for acute and chronic wounds; Stravix for tendon repair; TruSkin for wound closure; Cartiform, a viable cartilage mesh for cartilage repair, and BIO4 for bone growth. All of these products are cryo-preserved and stored in special freezers at -80 degrees Celsius.

The Company continues to advance its research and development of biotechnology by focusing on improvement in regenerative medicine, including bioengineering, stem cell research and viable tissue-based products. The Company's BioSmart cryopreservation process retains the native characteristics and inherent functionality of tissue. Its BioSmart process includes preservation of the three dimensional (3D) matrix, endogenous growth factors, and tissue-resident cells.


Grafix is a cryopreserved placental membrane. It consists of an extracellular matrix (ECM) rich in collagen, growth factors, fibroblasts, mesenchymal stem cells (MSCs), and epithelial cells native to the tissue. Grafix is applied directly to acute and chronic wounds. It is flexible and adheres to complex anatomies. Grafix is available in various sizes, providing optimal wound coverage from initial application through wound closure. It is suitable for a variety of hard-to-treat acute and chronic wounds, including but not limited to Diabetic foot ulcers, Burns, Deep tunneling wounds, Pressure ulcers, Pyoderma gangrenosum, Surgical dehiscence, Epidermolysis bullosa, Surgical incisions and Venous leg ulcers.


Stravix is a viable cryopreserved human placental tissue composed of umbilical amnion and Wharton's jelly. Stravix retains the native collagen and hyaluronic acid-rich extracellular matrix (ECM), endogenous growth factors, and endogenous cells, including epithelial cells, fibroblasts and MSCs found in placental tissue. It serves as an anti-adhesion, anti- inflammatory, and antimicrobial wrap to aid natural wound repair. Stravix is available in two sizes: 3 centimeters (cm) x 6 cm and 2 cm x 4 cm. It is used as a surgical covering or wrap for several procedures, including but not limited to Tendon Repair, Achilles Tendon Rupture, Bunionectomy, Hallux Rigidus Correction, Foot Amputations, Fibromatosis and Arthrodesis.


TruSkin is a split-thickness, cryopreserved human skin allograft that addresses unmet medical needs of chronic wounds. TruSkin retains the ECM, growth factors, and endogenous living skin cells of native tissue, making it an alternative to fresh skin allograft. TruSkin is optimally meshed to cover more wound area than competing skin allografts, while still allowing for proper wound drainage. TruSkin is available in two sizes: 4 cm x 8 cm (32 square centimeters) and 2 cm x 4 cm (eight square centimeters). TruSkin preserves the native components of human skin to promote natural wound repair. TruSkin can be used to repair acute or chronic wounds of various sizes, including those with exposed muscle, tendon, bone and/or joint capsule.


Cartiform is a cryopreserved viable osteochondral allograft for articular cartilage repair. Cartiform delivers the intact, dimensional architecture of hyaline cartilage right to the site of the defect, including the naturally occurring cellular and molecular components necessary for repair. Cartiform is manufactured and distributed by the Company, and is available through Arthrex, Inc.


BIO4 is a viable bone matrix containing endogenous bone forming cells, including MSCs, osteoprogenitor cells, osteoblasts, osteoinductive and angiogenic growth factors. BIO4 possesses all four characteristics involved in bone repair and regeneration: osteoconductive, osteoinductive, osteogenic and angiogenic. BIO4 contains naturally occurring angiogenic growth factors, such as the vascular endothelial growth factor (VEGF), platelet-derived growth factor (PDGF) and basic fibroblast growth factor (bFGF). BIO4 is manufactured and distributed by the Company and is available through Stryker Corporation.

Company Address

Osiris Therapeutics Inc

7015 Albert Einstein Dr
COLUMBIA   MD   21046-1707
P: +1443.5451800
F: +1443.5451701

Company Web Links